Understanding how breast cancer cells become resistant to treatment
DELINEATING THE EVOLUTION AND ECOLOGY OF CHEMORESISTANCE IN BREAST CANCER WITH SINGLE CELL GENOMICS
This study is looking at how triple-negative breast cancer changes and becomes resistant to chemotherapy, using advanced technology to understand the genetic changes in the tumor cells, with the hope of finding better treatment options for patients who have few choices right now.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10741817 on NIH RePORTER |
What this research studies
This research focuses on triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer that often becomes resistant to chemotherapy. By using advanced single-cell genomic technologies, the researchers aim to uncover how tumor cells evolve and adapt to treatment, leading to resistance. The study will analyze the genetic changes in tumor cells and their environment, providing insights into the mechanisms behind treatment failure. This knowledge could help identify new therapeutic strategies for patients who currently have limited options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer, particularly those who have undergone neoadjuvant chemotherapy.
Not a fit: Patients with other subtypes of breast cancer or those who have not received chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with triple-negative breast cancer who experience chemotherapy resistance.
How similar studies have performed: Other research has shown promising results using single-cell genomic approaches to study cancer evolution, indicating that this methodology could yield valuable insights.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Navin, Nicholas — University of Tx Md Anderson Can Ctr
- Study coordinator: Navin, Nicholas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.